Stratos Wealth Partners LTD. Reduces Holdings in Global X Genomics & Biotechnology ETF $GNOM

Stratos Wealth Partners LTD. trimmed its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 7.4% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 57,554 shares of the company’s stock after selling 4,630 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Global X Genomics & Biotechnology ETF were worth $485,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of GNOM. Oppenheimer Asset Management Inc. boosted its stake in Global X Genomics & Biotechnology ETF by 35.8% during the first quarter. Oppenheimer Asset Management Inc. now owns 82,923 shares of the company’s stock worth $659,000 after buying an additional 21,847 shares during the period. Creative Financial Designs Inc. ADV purchased a new position in Global X Genomics & Biotechnology ETF during the first quarter worth $95,000. Private Advisor Group LLC boosted its stake in Global X Genomics & Biotechnology ETF by 14.3% during the first quarter. Private Advisor Group LLC now owns 20,738 shares of the company’s stock worth $165,000 after buying an additional 2,587 shares during the period. Manhattan West Asset Management LLC boosted its stake in Global X Genomics & Biotechnology ETF by 13.0% during the first quarter. Manhattan West Asset Management LLC now owns 29,947 shares of the company’s stock worth $238,000 after buying an additional 3,439 shares during the period. Finally, HighTower Advisors LLC boosted its stake in Global X Genomics & Biotechnology ETF by 16.7% during the first quarter. HighTower Advisors LLC now owns 15,242 shares of the company’s stock worth $121,000 after buying an additional 2,184 shares during the period. 56.95% of the stock is owned by hedge funds and other institutional investors.

Global X Genomics & Biotechnology ETF Stock Up 1.0%

NASDAQ GNOM opened at $43.38 on Friday. The company has a fifty day moving average of $38.82 and a two-hundred day moving average of $34.94. The firm has a market capitalization of $52.92 million, a price-to-earnings ratio of -18.54 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 52 week low of $27.20 and a 52 week high of $44.65.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.